Literature DB >> 20153988

Identification and characterization of oxidation and deamidation sites in monoclonal rat/mouse hybrid antibodies.

Vera Timm1, Patrick Gruber, Michael Wasiliu, Horst Lindhofer, Dirk Chelius.   

Abstract

Oxidation of methionine residues and deamidation of asparagine residues are the major causes of chemical degradation of biological pharmaceuticals. The mechanism of these non-enzymatic chemical reactions has been studied in great detail. However, the identification and quantification of oxidation and deamidation sites in a given protein still remains a challenge. In this study, we identified and characterized several oxidation and deamidation sites in a rat/mouse hybrid antibody. We evaluated the effects of the sample preparation on oxidation and deamidation levels and optimized the peptide mapping method to minimize oxidation and deamidation artifacts. Out of a total number of 18 methionine residues, we identified six methionine residues most susceptible to oxidation. We determined the oxidation rate of the six methionine residues using 0.05% H(2)O(2) at different temperatures. Methionine residue 256 of the mouse heavy chain showed the fastest rate of oxidation under those conditions with a half life of approximately 200 min at 4 degrees C and 27 min at 37 degrees C. We identified five asparagine residues prone to deamidation under accelerated conditions of pH 8.6 at 37 degrees C. Kinetic characterization of the deamidation sites showed that asparagine residue 218 of the rat heavy chain exhibited the fastest rate of deamidation with a half live of 1.5 days at pH 8.6 and 37 degrees C. Analysis of antibody isoforms using free flow electrophoresis showed that deamidation is the major cause of the charged variants of this rat/mouse hybrid antibody. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20153988     DOI: 10.1016/j.jchromb.2010.01.036

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  11 in total

1.  Mass spectrometric distinction of in-source and in-solution pyroglutamate and succinimide in proteins: a case study on rhG-CSF.

Authors:  Mukesh Kumar; Amarnath Chatterjee; Anand P Khedkar; Mutyalasetty Kusumanchi; Laxmi Adhikary
Journal:  J Am Soc Mass Spectrom       Date:  2013-01-03       Impact factor: 3.109

2.  Simultaneous monitoring of oxidation, deamidation, isomerization, and glycosylation of monoclonal antibodies by liquid chromatography-mass spectrometry method with ultrafast tryptic digestion.

Authors:  Yi Wang; Xiaojuan Li; Yan-Hui Liu; Daisy Richardson; Huijuan Li; Mohammed Shameem; Xiaoyu Yang
Journal:  MAbs       Date:  2016-09-06       Impact factor: 5.857

3.  Structural and functional characterization of the trifunctional antibody catumaxomab.

Authors:  Dirk Chelius; Peter Ruf; Patrick Gruber; Matthias Plöscher; Reinhard Liedtke; Eva Gansberger; Juergen Hess; Michael Wasiliu; Horst Lindhofer
Journal:  MAbs       Date:  2010-05-16       Impact factor: 5.857

4.  Identification of potential sites for tryptophan oxidation in recombinant antibodies using tert-butylhydroperoxide and quantitative LC-MS.

Authors:  Miriam Hensel; Rebecca Steurer; Juergen Fichtl; Carsten Elger; Frank Wedekind; Andreas Petzold; Tilman Schlothauer; Michael Molhoj; Dietmar Reusch; Patrick Bulau
Journal:  PLoS One       Date:  2011-03-03       Impact factor: 3.240

5.  Simultaneous assessment of Asp isomerization and Asn deamidation in recombinant antibodies by LC-MS following incubation at elevated temperatures.

Authors:  Katharina Diepold; Katrin Bomans; Michael Wiedmann; Boris Zimmermann; Andreas Petzold; Tilman Schlothauer; Robert Mueller; Bernd Moritz; Jan Olaf Stracke; Michael Mølhøj; Dietmar Reusch; Patrick Bulau
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

6.  Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: Susceptibility vs. functionality of critical quality attributes.

Authors:  Markus Haberger; Katrin Bomans; Katharina Diepold; Michaela Hook; Jana Gassner; Tilman Schlothauer; Adrian Zwick; Christian Spick; Jochen Felix Kepert; Brigitte Hienz; Michael Wiedmann; Hermann Beck; Philipp Metzger; Michael Mølhøj; Constanze Knoblich; Ulla Grauschopf; Dietmar Reusch; Patrick Bulau
Journal:  MAbs       Date:  2014-01-17       Impact factor: 5.857

7.  Structure-based prediction of asparagine and aspartate degradation sites in antibody variable regions.

Authors:  Jasmin F Sydow; Florian Lipsmeier; Vincent Larraillet; Maximiliane Hilger; Bjoern Mautz; Michael Mølhøj; Jan Kuentzer; Stefan Klostermann; Juergen Schoch; Hans R Voelger; Joerg T Regula; Patrick Cramer; Apollon Papadimitriou; Hubert Kettenberger
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

8.  Deamidation and isomerization liability analysis of 131 clinical-stage antibodies.

Authors:  Xiaojun Lu; R Paul Nobrega; Heather Lynaugh; Tushar Jain; Kyle Barlow; Todd Boland; Arvind Sivasubramanian; Maximiliano Vásquez; Yingda Xu
Journal:  MAbs       Date:  2018-12-10       Impact factor: 5.857

9.  Structural characterization of a recombinant fusion protein by instrumental analysis and molecular modeling.

Authors:  Zhigang Wu; Peng Zhou; Xiaoxin Li; Hui Wang; Delun Luo; Huaiyao Qiao; Xiao Ke; Jian Huang
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

10.  Oxidation in the complementarity-determining regions differentially influences the properties of therapeutic antibodies.

Authors:  Tetyana Dashivets; Jan Stracke; Stefan Dengl; Alexander Knaupp; Jan Pollmann; Johannes Buchner; Tilman Schlothauer
Journal:  MAbs       Date:  2016-09-09       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.